Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemImmunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challengeA Method for Producing Protein Nanoparticles with Applications in VaccinesPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsA viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityPhase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adultsImproved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.Antigen reversal identifies targets of opsonizing IgGs against pregnancy-associated malariaPhase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responsesPhase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malariaIdentification and characterization of the Plasmodium yoelii PyP140/RON4 protein, an orthologue of Toxoplasma gondii RON4, whose cysteine-rich domain does not protect against lethal parasite challenge infectionRational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infectionsA randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.Subdomain 3 of Plasmodium falciparum VAR2CSA DBL3x is identified as a minimal chondroitin sulfate A-binding region.Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemicThe blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureNew candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.The immunological enhancement activity of propolis flavonoids liposome in vitro and in vivoPhase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.Anaemia in a phase 2 study of a blood stage falciparum malaria vaccineImmunogenicity studies of proteins forming the T4 phage head surface.The epitope of monoclonal antibodies blocking erythrocyte invasion by Plasmodium falciparum map to the dimerization and receptor glycan binding sites of EBA-175.Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunizedRelationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C.Microproteinuria during Opisthorchis viverrini infection: a biomarker for advanced renal and hepatobiliary pathologies from chronic opisthorchiasis.Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.Protective activity of the CnaBE3 domain conserved among Staphylococcus aureus Sdr proteins.Effects of age, hemoglobin type and parasite strain on IgG recognition of Plasmodium falciparum-infected erythrocytes in Malian children.
P2860
Q24273364-7F8F585F-80D9-4675-8A12-08B3E400E1E6Q26700012-F5D9D26D-C2CC-4872-B230-B5AB216AE445Q28484081-2FF9238A-C817-49B6-83E5-FBB2D5A9C3F7Q28545017-948F1010-A7F3-46F5-B40B-E336ADD7E2BAQ28550575-58C0A823-F634-4B0B-B8FC-FC88A81BE26AQ28731894-FB2C8F1F-9756-4B94-A207-7BDF0F663B73Q28740771-24EB8442-EBE2-40F9-B531-5165493A6951Q28749215-B870F2EF-A651-4AFB-9299-D5AE737B5A53Q30429455-56DBF63C-5427-4E02-B73F-FEF54BDB3384Q30603697-EDC18FF0-5982-48AA-910F-6C3E09CEF283Q33350210-1CE1CD65-8947-42D1-AEE3-2ECA7E9D89FBQ33356029-685311BB-5B03-42A3-AB3E-9594CFBA0479Q33359552-60157B15-4837-4150-A2AD-5449B3D43B35Q33361102-6BBFE01F-B731-4ECE-B960-3D374882C28AQ33572458-34DFB9D2-AC28-443F-971E-92FF88315FC5Q33587496-E547FE31-8FEB-4660-8934-CA7A3050604DQ33598040-98F20FF0-F701-4374-A72A-CA5EB5442130Q33762869-B8F36B65-6DC0-4808-885A-657B1CA01CFEQ33892507-5BBC8EA9-BF27-4C13-BCCC-55E6F3729016Q33939405-D7C2230D-A68D-4DC4-A812-505FE1850074Q33974904-D741CC71-8740-427F-968C-EC34F65B050DQ33987686-54F52ADF-B4C4-43E0-B551-D2A51C28F0C5Q34042744-F2254D24-E51E-4B31-BB2F-8FEC0F99BC2BQ34189972-03495410-5A4B-4FB0-ABF0-C11F6BE80625Q34241973-3593F1B0-9039-4BFA-8F3A-E6C4D30CBAA7Q34257253-1DD8DE5C-1D90-4A75-87B8-CBD3DC0F6D50Q34290768-EAD77F52-403C-4D87-A658-1A086051074EQ34341570-1FD26683-9891-4213-AC13-75E42B936405Q34419048-EB6BA1C9-C0E8-4115-8F3D-364ED2261FE1Q34441098-EE0EA5D1-830E-449C-9317-6EF9F9168782Q34509612-11368AA3-DD5B-457F-95EA-98E9074E7BD2Q34564544-23BE6486-07F9-4EC9-9B40-A6EE54671E0EQ34593930-F1D911F1-B939-4EA8-91E5-BB4EF6DF067EQ34606720-5AB85D21-FD68-4C7E-A13C-2629C2D42854Q34612788-0A0C304E-1D6D-4DD2-AB3F-7DE128C334D7Q34653470-6CBC14EA-21E4-4F5C-88BB-49DA8E672F8FQ34746708-BC66B598-9340-4199-90FA-B418170004F4Q34951967-666843BB-62CA-41D9-A964-91CAFA531C49Q34999275-8F4401C8-F414-4416-8CCE-DB2710AF3C2AQ35017067-5BB960DF-4995-44B7-91C7-D2EBC1070EE4
P2860
Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Development and characterizati ...... experimental malaria vaccines
@ast
Development and characterizati ...... experimental malaria vaccines
@en
type
label
Development and characterizati ...... experimental malaria vaccines
@ast
Development and characterizati ...... experimental malaria vaccines
@en
prefLabel
Development and characterizati ...... experimental malaria vaccines
@ast
Development and characterizati ...... experimental malaria vaccines
@en
P2860
P50
P1433
P1476
Development and characterizati ...... experimental malaria vaccines
@en
P2093
Andrew C Orcutt
Olga V Muratova
P2860
P304
P356
10.1016/J.VACCINE.2007.10.064
P407
P577
2007-11-20T00:00:00Z